FDA Approves Ipilimumab for Pediatric Melanoma

The FDA has expanded the approval of ipilimumab (Yervoy) to include the treatment of pediatric melanoma patients 12 years and older with unresectable or metastatic disease.

Source: CancerNetwork - July 25, 2017 Category: Cancer & Oncology Authors: Ian Ingram Tags: Melanoma News Pediatric Cancers Source Type: news